ClinicalTrials.gg
CompletedNCT00249834CONSORTUpdated Mar 30, 2018Results posted

Safety and Efficacy of Pre-defined, Fixed Dose of Gonal-f Pen Based on Subject Baseline Characteristics in Subjects Undergoing in Vitro Fertilization (IVF)

A Phase 4 interventional study of Gonal-f and Recombinant human chorionic gonadotrophin (r-hCG) in Infertility, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in France. Open to female participants aged 18 Years to 34 Years. Per ClinicalTrials.gov, last updated 2018-03-30.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Sep 2004, registered Nov 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
166
Allocation
Non-randomized
Ages
18 Years to 34 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing follitropin alfa in Infertility — 3 open to participants now, 4 under way, 1 of them phase 3. follitropin alfa · Infertility.

Enrollment
15th of 30
166 · median 159
Started
2004
with 1 other
Phase 4
13 of 30
1 open now
Registered
1st of 30
by date
Lead sponsor
8 of 30
Merck KGaA, Darmstadt, Germany

Among the 30 studies testing follitropin alfa in Infertility, this one is the 15th largest by enrollment, is one of 2 that started in 2004, is one of 13 in phase 4, and was the 1st registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

3 of the 30 studies testing follitropin alfa in Infertility are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About follitropin alfa

follitropin alfa: first FDA approval 1997 (Gonal-f), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 34 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing follitropin alfa in Infertility, or all of them as a file.
02

Study summary

Clinical validation of the assisted reproductive technology (ART) treatment guidelines, which determine the optimal dose of recombinant human follicle stimulating hormone (r-hFSH) based on subject baseline characteristics/predictors of ovarian response.

03

Conditions studied

  • Infertility

Browse trials for

Keywords

  • Assisted Reproductive Technology (ART)
  • Infertility
  • Ovarian stimulation
04

Who can participate

Ages eligible
18 Years to 34 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be an infertile subject justifying an in-vitro fertilization/embryo transfer (IVF/ET) treatment.
  • Have a male partner with semen analysis within the past six months prior to study entry considered adequate to proceed with regular insemination or intracytoplasmic sperm injection (ICSI) according to the center's standard practice. If these criteria are not met, the subject can only be entered if donor sperm will be used.
  • Be between her 18th and 35th birthday (35 not included).
  • Have a regular spontaneous ovulatory menstrual cycle between 21 and 35 days in length.
  • Have early follicular phase (Day 2-4) serum levels within the last 3 months prior to study entry of:
  • Follicle stimulating hormone (FSH) greater than or equal to (>=) 12 International units per liter (IU/L), and
  • Oestradiol (E2) within center's local normal laboratory range values.
  • Presence of both ovaries.
  • Have a uterine cavity without abnormalities, which, in the investigator's opinion, could impair embryo implantation or pregnancy evolution as assessed within the last 3 years using ultrasound (US), hysteroscopy (HSC), or hysterosalpingography (HSG).
  • Have a negative cervical papanicolaou (PAP) test within the last 6 months prior to study entry.
  • Have at least one wash-out cycle (defined as >= 30 days since the last dose of clomiphene citrate or gonadotrophin treatment) since the last ART cycle and/or clomiphene citrate or gonadotrophin treatment prior to starting gonadotrophin releasing hormone (GnRH) agonist therapy.
  • Have a negative pregnancy test prior to beginning GnRH agonist therapy.
  • Be willing and able to comply with the protocol for the duration of the study. Have given written , prior to any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to her future medical care.

Exclusion criteria

Exclusion Criteria:

  • Had 2 previous ART cycles with a poor response to gonadotrophin stimulation, defined as less than or equal to (\<=) 5 mature follicles and/or \<=3 oocytes collected in any previous IVF cycle or hyper response, defined as >=25 oocytes retrieved.
  • Any medical condition, which in the judgement of the investigator may interfere with the absorption, distribution, metabolism or excretion of the drug. In case of doubt, the subject in question should be discussed with Serono's Therapeutic Director.
  • Had previous severe ovarian hyperstimulation syndrome (OHSS).
  • A (BMI) greater than (>) 30 kilogram per square meter (kg/m\^2)
  • Any to being pregnant and/or carrying a pregnancy to term.
  • Extra-uterine pregnancy within the last 3 months.
  • History of 3 or more miscarriages (early or late miscarriages) due to any cause.
  • Tumours of the hypothalamus and pituitary gland.
  • Ovarian enlargement or cyst of unknown aetiology.
  • Ovarian, uterine or mammary cancer.
  • A systemic disease.
  • Known infection with (HIV), or C virus.
  • Abnormal gynaecological bleeding of undetermined origin.
  • Known allergy or to human gonadotrophin preparations.
  • Any active substance abuse or history of drug, medication or alcohol abuse in the past 5 years.
  • Entered previously into this study or simultaneous participation in another clinical trial
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    Gonal-f 112.5 IU

    Drug: Gonal-f · Drug: Recombinant human chorionic gonadotrophin (r-hCG)

  • Experimental
    Gonal-f 37.5 IU

    Drug: Gonal-f · Drug: Recombinant human chorionic gonadotrophin (r-hCG)

  • Experimental
    Gonal-f 75 IU

    Drug: Gonal-f · Drug: Recombinant human chorionic gonadotrophin (r-hCG)

  • Experimental
    Gonal-f 150 IU

    Drug: Gonal-f · Drug: Recombinant human chorionic gonadotrophin (r-hCG)

  • Experimental
    Gonal-f 187.5 IU

    Drug: Gonal-f · Drug: Recombinant human chorionic gonadotrophin (r-hCG)

  • Experimental
    Gonal-f 225 IU

    Drug: Gonal-f · Drug: Recombinant human chorionic gonadotrophin (r-hCG)

  • Experimental
    Gonal-f 262.5 IU

    Drug: Gonal-f · Drug: Recombinant human chorionic gonadotrophin (r-hCG)

  • Experimental
    Gonal-f 300 IU

    Drug: Gonal-f · Drug: Recombinant human chorionic gonadotrophin (r-hCG)

Interventions

  • GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.

    Also known as: follitropin alfa, Recombinant Human Follicle Stimulating Hormone (r-hFSH)

  • DrugRecombinant human chorionic gonadotrophin (r-hCG)

    When at least 1 follicle greater than or equal to (\>=) 18 millimeter (mm) and 2 follicles \>=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.

06

What researchers measure

Primary outcomes

  1. Number of Oocytes Retrieved

    Mean number of oocytes retrieved on the day of ovum pick up (OPU) was calculated. Oocyte retrieval was a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body. As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

    Time frame: Ovum pick up day (34 to 38 hours post r-hCG administration)

Secondary outcomes

  1. Total Dose of Recombinant Human Follicle Stimulating Hormone (r-hFSH)

    As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

    Time frame: up to end of stimulation cycle (approximately 31 days)

  2. Mean Number of Ovarian Stimulation Days

    The mean number of stimulation days were determined based on the treatment administration information collected in the case report form. Ovarian stimulation included time from first r-hFSH injection (stimulation Day) until day on which r-hCG was administered (r-hCG day). As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

    Time frame: up to end of stimulation cycle (approximately 31 days)

  3. Percentage of Cycles Cancelled Due to Excessive or Inadequate Response to r-hFSH

    As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

    Time frame: up to end of stimulation cycle (approximately 31 days)

  4. Number of Subjects Needing Dose Adjustment

    Number of subjects needing increase in dose, decrease in dose or increase and decrease both in dose were reported. As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

    Time frame: 6 days post r-hFSH treatment

  5. Mean Daily Recombinant Human Follicle Stimulating Hormone (r-hFSH) Dose

    As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

    Time frame: up to end of stimulation cycle (approximately 31 days)

  6. Embryo Implantation Rate

    Embryo implantation rate was measured as the number of gestational sacs observed divided by the number of embryos transferred multiplied by 100. As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

    Time frame: 35-42 days post r-hCG administration

  7. Overall Pregnancy Rate, Clinical Rate and Multiple Pregnancy Rate

    Overall pregnancy rate was defined as the percentage of subjects with serum beta-hCG levels greater than 10 IU/L. Clinical pregnancy rate was defined as the percentage of subjects with at least 1 ultrasound confirmed gestational sac, with or without foetal heart activity. Multiple pregnancy rate was defined as the percentage of subjects with more than 1 ultrasound confirmed gestational sac in the uterus with fetal heart activity. As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

    Time frame: 35-42 days post r-hCG administration

07

Results

Posted Mar 30, 2018

Participant flow

Participant flow — Overall Study
MilestoneGonal-f 37.5 IUGonal-f 75 IUGonal-f 112.5 IUGonal-f 150 IUGonal-f 187.5 IUGonal-f 225 IUGonal-f 262.5 IUGonal-f 300 IU
Started1484534241022
Completed029312619812
Not completed1191485210
Withdrew: Ovarian stimulation failed10000000
Withdrew: Failure of down-regulation00000010
Withdrew: Protocol violation0191485200

Outcome measures

PrimaryNumber of Oocytes Retrieved

Mean number of oocytes retrieved on the day of ovum pick up (OPU) was calculated. Oocyte retrieval was a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body. As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

Time frame:
Ovum pick up day (34 to 38 hours post r-hCG administration)
Reported as:
Mean · Oocytes
Number of Oocytes Retrieved
OocytesGonal-f 75 IUGonal-f 112.5 IUGonal-f 150 IUGonal-f 187.5 IUGonal-f 225 IU
Number of Oocytes Retrieved8.3 ± 4.59.6 ± 6.512.1 ± 6.412.7 ± 4.38.3 ± 3.8
SecondaryTotal Dose of Recombinant Human Follicle Stimulating Hormone (r-hFSH)

As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

Time frame:
up to end of stimulation cycle (approximately 31 days)
Reported as:
Mean · International Units (IU)
Total Dose of Recombinant Human Follicle Stimulating Hormone (r-hFSH)
International Units (IU)Gonal-f 75 IUGonal-f 112.5 IUGonal-f 150 IUGonal-f 187.5 IUGonal-f 225 IU
Total Dose of Recombinant Human Follicle Stimulating Hormone (r-hFSH)1102.3 ± 671.81287.2 ± 447.01632.4 ± 341.52043.8 ± 276.22572.5 ± 552.3
SecondaryMean Number of Ovarian Stimulation Days

The mean number of stimulation days were determined based on the treatment administration information collected in the case report form. Ovarian stimulation included time from first r-hFSH injection (stimulation Day) until day on which r-hCG was administered (r-hCG day). As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

Time frame:
up to end of stimulation cycle (approximately 31 days)
Reported as:
Mean · Days
Mean Number of Ovarian Stimulation Days
DaysGonal-f 75 IUGonal-f 112.5 IUGonal-f 150 IUGonal-f 187.5 IUGonal-f 225 IU
Mean Number of Ovarian Stimulation Days12.5 ± 4.411.0 ± 2.910.6 ± 1.811.0 ± 1.411.5 ± 2.4
SecondaryPercentage of Cycles Cancelled Due to Excessive or Inadequate Response to r-hFSH

As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

Time frame:
up to end of stimulation cycle (approximately 31 days)
Reported as:
Number · Percentage of cycles
Percentage of Cycles Cancelled Due to Excessive or Inadequate Response to r-hFSH
Percentage of cyclesGonal-f 75 IUGonal-f 112.5 IUGonal-f 150 IUGonal-f 187.5 IUGonal-f 225 IU
Excessive response0.00.02.90.00.0
Inadequate response25.08.98.88.320.0
SecondaryNumber of Subjects Needing Dose Adjustment

Number of subjects needing increase in dose, decrease in dose or increase and decrease both in dose were reported. As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

Time frame:
6 days post r-hFSH treatment
Reported as:
Number · subjects
Number of Subjects Needing Dose Adjustment
subjectsGonal-f 75 IUGonal-f 112.5 IUGonal-f 150 IUGonal-f 187.5 IUGonal-f 225 IU
Increase73310
Decrease00121
Increase and decrease both23000
SecondaryMean Daily Recombinant Human Follicle Stimulating Hormone (r-hFSH) Dose

As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

Time frame:
up to end of stimulation cycle (approximately 31 days)
Reported as:
Mean · IU/day
Mean Daily Recombinant Human Follicle Stimulating Hormone (r-hFSH) Dose
IU/dayGonal-f 75 IUGonal-f 112.5 IUGonal-f 150 IUGonal-f 187.5 IUGonal-f 225 IU
Mean Daily Recombinant Human Follicle Stimulating Hormone (r-hFSH) Dose84.4 ± 21.6114.7 ± 16.4153.6 ± 12.8186.5 ± 5.8223.3 ± 5.3
SecondaryEmbryo Implantation Rate

Embryo implantation rate was measured as the number of gestational sacs observed divided by the number of embryos transferred multiplied by 100. As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

Time frame:
35-42 days post r-hCG administration
Reported as:
Mean · Percent sacs per embryo
Embryo Implantation Rate
Percent sacs per embryoGonal-f 75 IUGonal-f 112.5 IUGonal-f 150 IUGonal-f 187.5 IUGonal-f 225 IU
Embryo Implantation Rate36.5 ± 42.824.3 ± 35.028.2 ± 38.937.1 ± 40.511.9 ± 20.9
SecondaryOverall Pregnancy Rate, Clinical Rate and Multiple Pregnancy Rate

Overall pregnancy rate was defined as the percentage of subjects with serum beta-hCG levels greater than 10 IU/L. Clinical pregnancy rate was defined as the percentage of subjects with at least 1 ultrasound confirmed gestational sac, with or without foetal heart activity. Multiple pregnancy rate was defined as the percentage of subjects with more than 1 ultrasound confirmed gestational sac in the uterus with fetal heart activity. As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

Time frame:
35-42 days post r-hCG administration
Reported as:
Number · Percentage of subjects
Overall Pregnancy Rate, Clinical Rate and Multiple Pregnancy Rate
Percentage of subjectsGonal-f 75 IUGonal-f 112.5 IUGonal-f 150 IUGonal-f 187.5 IUGonal-f 225 IU
Total pregnancy171816162
Clinical pregnancy151412122
Multiple pregnancy32430

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gonal-f 75 IU—3/48 (6.3%)11/48 (22.9%)
Gonal-f 112.5 IU—3/45 (6.7%)15/45 (33.3%)
Gonal-f 150 IU—1/34 (2.9%)5/34 (14.7%)
Gonal-f 187.5 IU—1/24 (4.2%)10/24 (41.7%)
Gonal-f 225 IU—0/10 (0%)3/10 (30%)
Most frequent serious events
Most frequent serious events
EventGonal-f 75 IUGonal-f 112.5 IUGonal-f 150 IUGonal-f 187.5 IUGonal-f 225 IU
Ovarian hyperstimulation syndromeReproductive system and breast disorders2/480/450/341/240/10
Ovarian torsionReproductive system and breast disorders0/480/451/340/240/10
Pelvic painReproductive system and breast disorders0/481/450/340/240/10
Ectopic pregnancyPregnancy, puerperium and perinatal conditions0/481/450/340/240/10
Urinary tract infectionInfections and infestations0/481/450/340/240/10
AbortionPregnancy, puerperium and perinatal conditions1/480/450/340/240/10
Imminent abortionPregnancy, puerperium and perinatal conditions1/480/450/340/240/10
Jugular vein thrombosisVascular disorders1/480/450/340/240/10
Most frequent other events
Showing 10 of 28
Most frequent other events
EventGonal-f 75 IUGonal-f 112.5 IUGonal-f 150 IUGonal-f 187.5 IUGonal-f 225 IU
HeadacheNervous system disorders2/487/450/345/241/10
Ovarian hyperstimulation syndromeReproductive system and breast disorders1/482/451/343/241/10
Breast painReproductive system and breast disorders0/480/450/340/241/10
Myasthenic syndromeNervous system disorders0/480/450/340/241/10
InfluenzaInfections and infestations1/480/450/340/241/10
PneumoniaInfections and infestations0/480/450/340/241/10
Abdominal painGastrointestinal disorders0/480/450/340/241/10
Pelvic painReproductive system and breast disorders0/481/450/341/241/10
Vaginal haemorrhageReproductive system and breast disorders3/480/450/340/240/10
Abdominal pain upperGastrointestinal disorders0/480/452/340/240/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Gonal-f 37.5 IUGonal-f 75 IUGonal-f 112.5 IUGonal-f 150 IUGonal-f 187.5 IUGonal-f 225 IUGonal-f 262.5 IUGonal-f 300 IUTotal
<=18 years000000000
Between 18 and 65 years1484534241022166
>=65 years000000000
Sex: Female, Male
Sex: Female, Male(Participants)Gonal-f 37.5 IUGonal-f 75 IUGonal-f 112.5 IUGonal-f 150 IUGonal-f 187.5 IUGonal-f 225 IUGonal-f 262.5 IUGonal-f 300 IUTotal
Female1484534241022166
Male000000000
08

Study locations

1 site
  • Medical Information
    Paris, France
09

References and documents

Publications

  • Olivennes F, Howles CM, Borini A, Germond M, Trew G, Wikland M, Zegers-Hochschild F, Saunders H, Alam V; CONSORT study group. Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. Reprod Biomed Online. 2009 Feb;18(2):195-204. doi: 10.1016/s1472-6483(10)60256-8. PubMed 19192339 ↗
  • Olivennes F, Howies CM, Borini A, Germond M, Trew G, Wikland M, Zegers-Hochschild F, Saunders H, Alam V. Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. Reprod Biomed Online. 2011 Feb;22 Suppl 1:S73-82. doi: 10.1016/S1472-6483(11)60012-6. PubMed 21575853 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2004 to primary completion in Jan 2006, 15 months.

Results were first posted in Mar 2018, 12 years 2 months after primary completion.

Of 81 phase 4 interventional studies under Infertility, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 82. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2005
First posted
Nov 7, 2005
StartActual
Sep 22, 2004
Primary completionActual
Jan 16, 2006
CompletionActual
Jan 16, 2006
Results first posted
Mar 30, 2018
Last update
Mar 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00249834
Responsible party
Sponsor
First posted
Nov 7, 2005
Start date
Sep 22, 2004
Primary completion
Jan 16, 2006
Completion
Jan 16, 2006
Results posted
Mar 30, 2018
Last update
Mar 30, 2018

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin alfa

Start the discussion